Nexlife: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Nexlife’s website, https://nexlife.us, FDA Establishment Identifier (FEI) 3044820290, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.

1. 1

   “1. The compounded semaglutide and tirzepatide products displayed on your website identify “Nexlife” on the pictured label, suggesting Nexlife is the compounder of those drugs when in fact it is not.”

2. 2

   “See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”)”

3. 3

   “In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&C Act”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

nexlife.us returned a live storefront on 2026-08-09 titled "Nexlife", advertising "Semaglutide Weight Loss Online Prices start from $165 per month*" and GLP-1 treatment "As low as $155 /mo*" on a 12-month plan, with add-to-cart markup present in the page.

Strip a letter down to one sentence and you can see exactly what it does and does not touch. Nothing here is about the medicine, the dose, the price or the clinic. It is about a name printed on a vial, and FDA's position — set out in the regulation it cites — is that putting your name on a drug label unqualified means you made it. Nexlife did not. For a reader comparing monthly prices, that matters in a narrow, practical way: the company setting the price and the company compounding the drug are two different businesses, and the label as pictured did not let you tell them apart. It says nothing about whether $155 a month is a good deal or a bad one. It says the branding on the box was not evidence of who was behind it, so any confidence you drew from seeing a name on the product has to be rebuilt from somewhere else.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Nexlife failed to respond.